Advanced Technology Laboratories
This article was originally published in The Gray Sheet
Preliminary second quarter results put revenues at $75 mil., down from $77 mil. in the year-ago quarter and "below management expectations," the firm says in a July 13 press release. Sales suffered from "the uncertain impact of U.S. health care reform legislation." ATL expects to report a loss of $1.5 mil. to $2 mil. due to the revenue shortfall, higher R&D costs, and expenses associated with the introduction of the Extended Signal Processing upgrade for the Ultramark 9 ultrasound system with High Definition Imaging ("The Gray Sheet" April 26, I&W-2). For the second quarter of 1992, the firm recorded a loss of $2.1 mil.; the loss included $5 mil. in nonrecurring charges related to the division of Westmark International into two companies: ATL and SpaceLabs Medical. The firm also reports that as of the close of the second quarter, it has repurchased 469,000 shares of stock under a 1 mil. share repurchase program, bringing outstanding shares to 10.8 mil....
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.